Adamax vs Cerebrolysin
A side-by-side research comparison of Adamax and Cerebrolysin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Adamax | Cerebrolysin |
|---|---|---|
| Full name | Adamax (Semax Analog Nootropic Peptide) | Cerebrolysin (Brain-Derived Peptide Preparation) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research peptide | Investigational |
| Mechanism | As an ACTH/melanocortin-derived peptide analog, it is proposed to elevate BDNF and other neurotrophic factors, modulate the dopaminergic and serotonergic systems, and provide neuroprotection, similar to but reportedly more potent and longer-acting than Semax. | Contains fragments mimicking NGF, BDNF, GDNF, CNTF. Enhances synaptic plasticity, promotes neuronal sprouting, reduces amyloid-beta, and stabilizes calcium homeostasis. |
| Molecular weight | ~ (short peptide) | <10,000 Da (peptide fraction) |
| Half-life | Short (extended vs Semax) | 4-6 hours |
| Bioavailability | Intranasal or subcutaneous | High (IM/IV) |
| Typical dose | Low microgram-to-milligram range (research) | 5-30 mL |
| Frequency | 1-2x daily | Daily for 10-20 days |
| Route | Intranasal or subcutaneous | Intramuscular or IV |
Adamax reported benefits
- Cognitive enhancement and focus
- Memory support
- Neuroprotection
- BDNF elevation (proposed)
- Mood support
Cerebrolysin reported benefits
- Neurotrophic support
- Stroke recovery
- Memory improvement
- Neuroprotection
- Synaptic plasticity
- Approved in 40+ countries
Related comparisons
Research and educational reference only. Not medical advice.